This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Egcg (Green Tea Extract)
EGCG is the dominant catechin in green tea (~30–50% of total polyphenols).
Aliases (1)
Overview
What is Egcg (Green Tea Extract)?
EGCG is the dominant catechin in green tea (~30–50% of total polyphenols). Drink the tea, mostly skip the pills. Brewed green tea or matcha at 1–3 cups/day gives 100–300 mg EGCG plus L-theanine in a food matrix and is essentially safe. Standardized extract capsules at 270–450 mg EGCG/day are an OPTIONAL-ADD for a fat-loss/cut phase or focused metabolic protocol — taken with food, never fasted, never as a bolus. Cap supplemental EGCG at the EFSA 800 mg/day ceiling. Hepatotoxicity is rare but real and idiosyncratic (HLA-B*35:01 carriers ~5–7× over-represented in case reports). For a 20yo MMA athlete with no caffeine baseline and clean baseline ALT/AST, daily brewed green tea is the clean play; isolated EGCG only earns a spot during a cut.
Peptide Interactions
The best-evidenced thermogenic + fat-oxidation stack. Most fat-loss meta-analyses are EGCG + caffeine, not standalone EGCG. Pre-training timing optimal.
(already in tea matrix, ~20–50 mg per cup): Cognitive synergy (calm alertness) and physiologically anchors the EGCG-with-food preference.
Stabilizes EGCG in GI tract, marginally improves bioavailability, and counteracts the iron-chelation effect when taken with iron-containing meals.
Complementary anti-inflammatory and cardiovascular signals; no direct interaction.
Polyphenol stack with overlapping AMPK/NF-κB/Nrf2 pathway effects. Modest additive effect on biomarkers; redundancy at high doses.
Neutral co-administration; standard athletic stack overlap.
Separate by ≥1 hour. Especially relevant for menstruating women, vegans, and athletes with low ferritin.
Both hepatic; combined oxidative load on glutathione system. Avoid high-dose chronic combination, especially fasted.
EGCG extract supplementation adds hepatic insult to drugs that already have a DILI signal. Skip extract; tea is fine.
Theoretical COMT-inhibition potentiation. In vivo signal is small (Lorenz 2014) but interaction databases flag this. For a stimulant user, EGCG via tea is fi…
Theoretical pressor risk via prolonged catecholamine signaling; sparse human data. Caution warranted.
EGCG affects platelet aggregation and CYP enzymes involved in warfarin metabolism. Monitor INR if combining.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety 6
Side Effects
- 1GI upset, nausea, abdominal discomfort — especially with extract capsules on an empty stomach. ~5–10%. Mitigation: always take with food.
- 2Astringent mouthfeel, tannin sensitivity, tooth staining — chronic tea drinkers.
- 3Diuretic effect / increased urinary frequency — mild.
- 4Headache — usually transient.
- 5Insomnia — primarily from the caffeine in non-decaffeinated extracts or late-day tea. Pure EGCG isn't a stimulant.
- 6Anxiety / tachycardia — caffeine-mediated in non-decaf products. Pure EGCG doesn't drive this.
When to Stop
- Idiosyncratic hepatotoxicity / acute liver injury — this is the headline safety concern, and it is real.
- Incidence: rare but non-trivial. USP catalogued 51 case reports across the 2008–2020 window from doses 250–1800 mg EGCG/day. DILIN registry has tracked it as a recurring herbal DILI cause.
- Risk amplifiers: (1) fasted bolus dosing; (2) doses >800 mg EGCG/day chronic; (3) extract supplements vs brewed tea (concentration + delivery vehicle); (4) HLA-B*35:01 carrier status (5–7× over-represented in cases; 16–20% of European-ancestry population are carriers); (5) low-activity COMT and UGT1A4 polymorphisms ([PMID 36178169](https://pubmed.ncbi.nlm.nih.gov/36178169/)); (6) concurrent hepatotoxic medications (acetaminophen, isoniazid, statins, methotrexate); (7) underlying liver disease / elevated baseline ALT.
- Clinical pattern: hepatocellular injury (ALT/AST elevation, sometimes 10–50× ULN), median onset 60–120 days from start. Most cases reversible on discontinuation; rare cases progress to acute liver failure / transplant / death.
- Watch protocol: baseline ALT/AST before starting extract supplementation; recheck at 4–8 weeks if dose >300 mg/day chronic; stop immediately on jaundice, dark urine, fatigue, or right-upper-quadrant pain.
- Iron-deficiency anemia (case reports from heavy tea drinkers): EGCG chelates non-heme iron in GI tract. 150 mg EGCG → ~14% reduction in non-heme iron absorption; 300 mg → 27% reduction. Largely irrelevant in iron-replete subjects on mixed diets, but vegetarian/menstruating users should separate tea/EGCG from iron-rich meals or supplements by ≥1 hour (and pair iron with vitamin C). Rare case reports of severe IDA in chronic heavy tea drinkers.
- Drug interaction via CYP1A2, CYP2C9, CYP3A4 modulation: EGCG modestly inhibits multiple CYPs. Clinically relevant for narrow-therapeutic-index drugs (warfarin, certain statins, tacrolimus) — flag for physician if on prescribed therapy.
- Folate antagonism (theoretical, pregnancy): EGCG inhibits dihydrofolate reductase in vitro. Some animal data show fetal abnormalities at high doses. Pregnancy: limit to dietary tea, avoid high-dose extracts.
- Thyroid concern (mild, theoretical): Animal data on goiter at extreme doses; not clinically relevant at human dietary or supplement levels.
- Baseline + first 8 weeks: ALT/AST baseline → repeat at 4–8 weeks if dose ≥300 mg/d chronic.
- First 2 weeks: GI tolerance — if persistent nausea, halve the dose or stop.
- Chronic (>3 months): annual ALT/AST as part of standard bloodwork.
References
EFSA 2018 — Scientific opinion on the safety of green tea catechins
regulatory cornerstone, 800 mg EGCG/day supplement cap, hepatotoxicity threshold.
View StudyUSP comprehensive review of GTE hepatotoxicity 2020 (PMID 32140423)
51 case-report analysis, label-warning update.
View StudyHLA-B*35:01 and green tea-induced liver injury — Hoofnagle et al. 2020
DILIN cohort, 5–7× over-representation in cases.
View StudyMechanism of HLA-B*35:01-mediated EGCG hepatotoxicity — Chem Res Toxicol 2024
T-cell activation pathway.
View StudyHepatotoxicity with high-dose GTE: COMT and UGT1A4 genotypes — Yu et al. 2022 (PMID 36178169)
Minnesota Green Tea Trial pharmacogenomic substudy.
View StudyHodgson, Randell, Jeukendrup 2013 — GTE on fat oxidation review
A-tier review of fat-oxidation evidence.
View StudyKhalesi 2014 — green tea catechins and blood pressure systematic review
modest BP reduction meta-analysis.
View StudyFront Nutr 2023 — green tea on cardiovascular risk factors
LDL/total-cholesterol meta-analysis.
View Study2024 meta-analysis — green tea catechin + exercise on body composition
most recent body-composition pooled analysis.
View StudyLiver-related safety of GTE — Isomura systematic review of RCTs
RCT-only safety summary.
View StudyZhou et al. 2005 — EGCG COMT inhibition structure-activity (PMID 15857617)
in vitro COMT inhibition IC50 data.
View StudyLorenz 2014 — COMT activity not impaired by high-dose EGCG in vivo (PMID 24972245)
clinical pharmacology rebuttal.
View StudyFang et al. 2003 — DNMT inhibition by EGCG (PMID 14633667)
DNMT mechanism foundational paper.
View StudyBerletch et al. 2007 — telomerase mechanism via hTERT promoter demethylation (PMID 17570133)
epigenetic chemoprevention mechanism.
View StudyTEAVIGO and nonhaem iron absorption — Schlemmer 2005 (PMID 16008116)
iron-absorption interaction quantified at supplemental EGCG doses.
View StudyGreen tea LiverTox monograph — NCBI Bookshelf NBK547925
clinical reference compiled by NIDDK for DILI clinicians.
View StudyAcute liver injury — Heliyon 2024 case report
12697-7) — recent severe IDA case in a heavy tea drinker.
View StudyCognitive Vitality EGCG report (Alzheimer's Drug Discovery Foundation)
synthesis on cognitive/neuroprotection signals.
View Study2025 Clinical and Translational Science — 720 mg EGCG × 30 days folate safety
recent safety signal at therapeutic dose.
View StudyTamara Rubin 2024–2025 matcha heavy-metal testing
independent third-party heavy-metal testing of commercial matcha brands.
View Studydopamine.club EGCG community report aggregate
community dose distribution + stack synergies.
View StudyLatest research
- metaDoes green tea catechin enhance weight-loss effect of exercise training in overweight and obese individuals — meta-analysisEight RCTs combined; exercise + green tea catechin produced significantly greater weight reduction than exercise + placebo, with the magnitude largest in trials using 500–800 mg EGCG/day for 8–12 weeks.
- mechanismInvestigating the immune basis of green tea extract induced liver injury in healthy donors expressing HLA-B*35:01EGCG primes PBMCs and activates T-cells in vitro in HLA-B*35:01 carriers — strong mechanistic case for an immune-mediated idiosyncratic liver injury, explaining why hepatotoxicity is unpredictable and not strictly dose-dependent.
- pharmacogenomicHepatotoxicity with high-dose green tea extract: effect of COMT and UGT1A4 genotypesMinnesota Green Tea Trial subjects with low-activity COMT and UGT1A4 polymorphisms had significantly larger ALT/AST rises on 1315 mg/day GTE for 12 months, identifying pharmacogenomic susceptibility groups.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.